XERS (Xeris Biopharma Holdings) Operating Cash Flow per Share : $-0.18 (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings Operating Cash Flow per Share?

Xeris Biopharma Holdings's operating cash flow per share for the three months ended in Mar. 2025 was $-0.07. Xeris Biopharma Holdings's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.18.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 40.70% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 42.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Xeris Biopharma Holdings's Operating Cash Flow per Share or its related term are showing as below:

XERS' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 18.6 Med: 41.6 Max: 45
Current: 40.7

During the past 9 years, Xeris Biopharma Holdings's highest 3-Year average Operating Cash Flow per Share Growth Rate was 45.00% per year. The lowest was 18.60% per year. And the median was 41.60% per year.

XERS's 3-Year OCF Growth Rate is ranked better than
82.2% of 1219 companies
in the Biotechnology industry
Industry Median: 9.2 vs XERS: 40.70

Xeris Biopharma Holdings Operating Cash Flow per Share Historical Data

The historical data trend for Xeris Biopharma Holdings's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Operating Cash Flow per Share Chart

Xeris Biopharma Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-1.89

-1.21

-0.76

-0.34

-0.25

Xeris Biopharma Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.14	-0.07	-0.06	0.01	-0.07

Competitive Comparison of Xeris Biopharma Holdings's Operating Cash Flow per Share

For the Biotechnology subindustry, Xeris Biopharma Holdings's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xeris Biopharma Holdings's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Xeris Biopharma Holdings's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Xeris Biopharma Holdings Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Xeris Biopharma Holdings's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-36.981	/	146.773
	=	-0.25

Xeris Biopharma Holdings's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	-10.031	/	152.446
	=	-0.07

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.18

Xeris Biopharma Holdings Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Xeris Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (NAS:XERS) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

0A8E:UK 2B30:Germany

Address

1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Executives

Beth Hecht	officer: See Remarks	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
John P. Schmid	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Jeffrey W Sherman	director	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Steven Pieper	officer: Chief Financial Officer	XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Dawn Halkuff	director	C/O XERIS PHARMACEUTICALS, 180 N. LASALLE ST., STE. 1800, CHICAGO IL 60601
Shannon John Patrick Jr	officer: See Remarks	DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Paul R Edick	director, officer: See Remarks	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Ricki Louise Fairley	director	XERIS BIOPHARMA HOLDINGS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Steven Prestrelski	officer: Chief Scientific Officer	C/O XERIS PHARMACEUTICALS, 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Marla Persky	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
John Johnson	director	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Kenneth Erland Johnson	officer: See Remarks	C/O XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Garheng Kong	director	712 COLLEGE AVENUE, MENLO PARK CA 94025
Barbara-jean Anne Bormann-kennedy	director	1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144
Barry M. Deutsch	officer: See Remarks	OVATION PHARMACEUTICALS, INC. FOUR PARKWAY NORTH, SUITE 200 DEERFIELD IL 60015